Legal entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention 340B Drug Pricing Program, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention 340B Drug Pricing Program, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. At 6, the average consequence score sits above the same-window beat average of 5.8. Section 232 of the Trade Expansion Act appears in 1 tracked Legal story from August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 31 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Section 232 of the Trade Expansion Act. Shared-story counts are live from our verified record — not editorial picks.
The Trump administration’s generic drug tariff announcement raises critical legal questions. Without a Federal Register proclamation or annex of tariff lines, the impending 100% duty faces uncertainty under trade law. This analysis examines the Section 232 authority and the regulatory void affecting contracts and compliance.
Source: clinicalleader.com · pharmaceuticalonline.com
Section 232 of the Trade Expansion Act is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
